American Academy of Pediatrics Committee on Drugs: “Inactive” ingredients in pharmaceutical products: Update (subject review). Pediatrics, 99:268–278, 1997.
2.
AndradeC: Bioequivalence of generic drugs. J Clin Psychiatry, 76:e1130–e1131, 2015.
3.
AndradeC: Cost of treatment as a placebo effect in psychopharmacology: Importance in the context of generic drugs. J Clin Psychiatry, 76:e534–e536, 2015.
4.
BorgheiniG: The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther, 25:1578–1592, 2003.
5.
ConnarnJN, FlowersS, KellyM, LuoR, WardKM, HarringtonG, MoncionI, KamaliM, McInnisM, FengMR, EllingrodV, BabiskinA, ZhangX, SunD: Pharmacokinetics and pharmacogenomics of bupropion in three different formulations with different release kinetics in healthy human volunteers. AAPS J, 19:1513–1522, 2017.
6.
DantaM, GhineaN: The complex legal and ethical issues related to generic medications. Viral hepatitis: A case study. J Virus Erad, 3:77–81, 2017.
7.
DesmaraisJE, BeauclairL, MargoleseHC: Switching from brand-name to generic psychotropic medications: A literature review. CNS Neurosci Ther, 17:750–760, 2011.
8.
HottingerM, LiangBA: Deficiencies of the FDA in evaluating generic formulations: Addressing narrow therapeutic index drugs. Am J Law Med, 38:667–689, 2012.
9.
WoodcockJ, KhanM, YuLX: Withdrawal of generic budeprion for nonbioequivalence. N Engl J Med, 367:2463–2465, 2012.
